HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lala, P. Articles by Lingwood, C. A. Search for Related Content PubMed PubMed Citation Articles by Lala, P. Articles by Lingwood, C. A. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 9, 6246-6251, March 3, 2000

Retroviral Transfection of Madin-Darby Canine Kidney Cells with Human MDR1 Results in a Major Increase in Globotriaosylceramide and 10⁵- to 10⁶-Fold Increased Cell Sensitivity to Verocytotoxin
ROLE OF P-GLYCOPROTEIN IN GLYCOLIPID SYNTHESIS^*

Prateek Lala, Shinya Ito^§¶, and Clifford A. Lingwood^¶**

From the Departments of  Laboratory Medicine & Pathobiology, ^§ Pediatrics, and  Biochemistry, University of Toronto and the ^¶ Research Institute, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

Retroviral infection of the Madin-Darby canine kidney (MDCK) renal cell line with human MDR1 cDNA, encoding the P-glycoprotein (P-gp) multidrug resistance efflux pump, induces a major accumulation of the glycosphingolipid (GSL), globotriaosylceramide (Gal1-4Gal1-4glucosylceramide-Gb₃), the receptor for the E. coli-derived verotoxin (VT), to effect a ~million-fold increase in cell sensitivity to VT. The shorter chain fatty acid isoforms of Gb₃ (primarily C16 and C18) are elevated and VT is internalized to the endoplasmic reticulum/nuclear envelope as we have reported for other hypersensitive cell lines. P-gp (but not MRP) inhibitors, e.g. ketoconazole or cyclosporin A (CsA) prevented the increased Gb₃ and VT sensitivity, concomitant with increased vinblastine sensitivity. Gb₃ synthase was not significantly elevated in MDR1-MDCK cells and was not affected by CsA. In MDR1-MDCK cells, synthesis of fluorescent N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-aminocaproyl (NBD)-lactosylceramide (LacCer) and NBD-Gb₃ via NBD-glucosylceramide (GlcCer) from exogenous NBD-C⁶-ceramide, was prevented by CsA. We therefore propose that P-gp can mediate GlcCer translocation across the bilayer, from the cytosolic face of the Golgi to the lumen, to provide increased substrate for the lumenal synthesis of LacCer and subsequently Gb₃. These results provide a molecular mechanism for the observed increased sensitivity of multidrug-resistant tumors to VT and emphasize the potential of verotoxin as an antineoplastic. Two strains (I and II) of MDCK cells, which differ in their glycolipid profile, have been described. The original MDR1-MDCK parental cell was not specified, but the MDR1-MDCK GSL phenotype and glycolipid synthase activities indicate MDCK-I cells. However, the partial drug resistance of MDCK-I cells precludes their being the parental cell. We speculate that the retroviral transfection per se, or the subsequent selection for drug resistance, selected a subpopulation of MDCK-I cells in the parental MDCK-II cell culture and that drug resistance in MDR1-MDCK cells is thus a result of both MDR1 expression and a second, previously unrecognized, component, likely the high level of GlcCer synthesis in these cells.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. F. De Rosa, C. Ackerley, B. Wang, S. Ito, D. M. Clarke, and C. Lingwood Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog J. Biol. Chem., February 22, 2008; 283(8): 4501 - 4511. [Abstract] [Full Text] [PDF]

				D. C. Smith, D. J. Sillence, T. Falguieres, R. M. Jarvis, L. Johannes, J. M. Lord, F. M. Platt, and L. M. Roberts The Association of Shiga-like Toxin with Detergent-resistant Membranes Is Modulated by Glucosylceramide and Is an Essential Requirement in the Endoplasmic Reticulum for a Cytotoxic Effect Mol. Biol. Cell, March 1, 2006; 17(3): 1375 - 1387. [Abstract] [Full Text] [PDF]

				C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 Drug Metab. Dispos., April 1, 2005; 33(4): 537 - 546. [Abstract] [Full Text] [PDF]

				E. Norris-Cervetto, R. Callaghan, F. M. Platt, R. A. Dwek, and T. D. Butters Inhibition of Glucosylceramide Synthase Does Not Reverse Drug Resistance in Cancer Cells J. Biol. Chem., September 24, 2004; 279(39): 40412 - 40418. [Abstract] [Full Text] [PDF]

				A. A. Khine, P. Tam, A. Nutikka, and C. A. Lingwood Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity Glycobiology, August 1, 2004; 14(8): 701 - 712. [Abstract] [Full Text] [PDF]

				M. F. De Rosa, D. Sillence, C. Ackerley, and C. Lingwood Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis J. Biol. Chem., February 27, 2004; 279(9): 7867 - 7876. [Abstract] [Full Text] [PDF]

				K. Hidemura, Y. L. Zhao, K. Ito, A. Nakao, Y. Tatsumi, H. Kanazawa, K. Takagi, M. Ohta, and T. Hasegawa Shiga-Like Toxin II Impairs Hepatobiliary Transport of Doxorubicin in Rats by Down-Regulation of Hepatic P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1636 - 1642. [Abstract] [Full Text] [PDF]

				C. Chen, E. Hanson, J. W. Watson, and J. S. Lee P-Glycoprotein Limits the Brain Penetration of Nonsedating but not Sedating H1-Antagonists Drug Metab. Dispos., March 1, 2003; 31(3): 312 - 318. [Abstract] [Full Text] [PDF]

				L. L. W. Cooling, D. S. Zhang, S. J. Naides, and T. A. W. Koerner Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts Blood, January 15, 2003; 101(2): 711 - 721. [Abstract] [Full Text] [PDF]

				I. Plo, G. Lehne, K. J. Beckstrom, N. Maestre, A. Bettaieb, G. Laurent, and D. Lautier Influence of Ceramide Metabolism on P-Glycoprotein Function in Immature Acute Myeloid Leukemia KG1a Cells Mol. Pharmacol., August 1, 2002; 62(2): 304 - 312. [Abstract] [Full Text] [PDF]

				G. van Meer and Q. Lisman Sphingolipid Transport: Rafts and Translocators J. Biol. Chem., July 12, 2002; 277(29): 25855 - 25858. [Full Text] [PDF]

				Y.-Y. LIU, T.-Y. HAN, A. E. GIULIANO, and M. C. CABOT Ceramide glycosylation potentiates cellular multidrug resistance FASEB J, March 1, 2001; 15(3): 719 - 730. [Abstract] [Full Text] [PDF]

				G. van Meer What sugar next? Dimerization of sphingolipid glycosyltransferases PNAS, February 13, 2001; 98(4): 1321 - 1323. [Full Text] [PDF]

				G. D. Luker, T. P. Flagg, Q. Sha, K. E. Luker, C. M. Pica, C. G. Nichols, and D. Piwnica-Worms MDR1 P-glycoprotein Reduces Influx of Substrates without Affecting Membrane Potential J. Biol. Chem., December 21, 2001; 276(52): 49053 - 49060. [Abstract] [Full Text] [PDF]